3-(R)-Piperidinyl Phthalimide D-(-)-tartaric acid steps in as a specialized compound with a role in creative organic synthesis and pharmaceutical applications. As a combination of a phthalimide-derived piperidine and D-(-)-tartaric acid, the molecular construction bridges a bicyclic imide structure and an enantiomerically pure acid, handing over a chiral element important for selectivity in advanced synthesis. In real-world scenarios, this meaning isn’t abstract — products built around this backbone can shift the course of a pathway, opening up routes for new, more effective pharmaceutical agents and intermediates.
This material brings together two distinct groups: the 3-(R)-piperidinyl phthalimide, which provides a complex, rigid structure, and D-(-)-tartaric acid, which infuses chirality as well as two adjacent hydroxyl groups. The chemical formula commonly reads as C17H20N2O8, though slight modifications can swing some atomic values depending on salt forms or raw inputs. The actual backbone of the molecule, pictured on a page or built in a lab, shows two main blocks joined at a nitrogen atom: the aromatic, planar face of phthalimide yielding to the deliberately contorted ring of piperidine, capped and made acidic by the D-(-)-tartaric segment.
Experience handling this compound points to a firm, crystalline solid, manifesting as off-white flakes or fine powder, sometimes observed as a pearl-like dense solid under low humidity. With a density typically hovering close to 1.42 g/cm3, it doesn’t flow like sand or dissolve with a snap. This material can show slight solubility in water but prefers certain organic solvents. Stored at room temperature, the compound stays stable. Heating above 140°C sometimes brings decomposition rather than a classic melt, so direct flame or hot plates aren’t welcome. Crystals measure small, but their facet-rich nature means purity standards are often visible without special optics.
3-(R)-Piperidinyl Phthalimide D-(-)-tartaric acid heads to industry mostly as a solid: powder, flakes, or, less frequently, pressed pearls. Particle size and bulk density matter — both dictate mixing in pharmaceutical blending, or how it dissolves in a reactor for further chemical synthesis. The product packs with a purity not less than 98% in commercial lots, reflecting high demand for enantiopure intermediates in drug research. Moisture content sits under 1%, and suppliers often guarantee low contamination from metals, residual solvents, and byproducts.
On the trade side, customs and logistics use the harmonized code (HS Code) 2924.29, where amides, imides, and derivatives — especially those holding pharmaceutical or research promise — find their place. Import and export rely on paperwork showing the IUPAC and CAS number, and documentation often lists its use as a raw material in advanced synthesis projects, not as a final drug or food additive.
This is not a food-grade chemical and doesn’t deserve casual handling. Industry data — along with chemical hazard statements — lists the product as potentially harmful if mishandled. Direct contact with skin or eyes may cause irritation, and inhalation of dust should be kept to zero thanks to possible respiratory side effects. Gloves, eye protection, and proper fume extraction remove those risks. Material Safety Data Sheets (MSDS) typically mark the item as non-flammable in regular lab scenarios. Still, with the presence of phthalimide and tartaric acid motifs, accidental ingestion or improper storage prompt a call to poison control. Proper storage relies on a cool, dry space, far from oxidizing materials or bases. Emergency procedures for spills involve collection with minimal dust generation and prompt disposal following hazardous waste guidelines — because an intermediate might not be benign in all contexts.
The path from raw material to finished drug or catalyst often passes through subtle, single-use synthons or chiral auxiliaries like 3-(R)-Piperidinyl Phthalimide D-(-)-tartaric acid. Chemists trust its structure for asymmetric synthesis; it pulls off enantiomeric enrichment in reactions where a generic acid or base couldn’t. Its piperidinyl group grants flexibility for N-alkylation, while tartaric acid’s geometry pins down stereochemistry in key bond-forming steps. Years in laboratories have shown that substituting racemic or impure versions means losing time, yield, and sometimes regulatory approval, so highly specced batches usually command a price justified by tight downstream controls.
Risks focus on a few straight lines. Manufacturing requires steady hands and accurate weighing because excess tartaric acid or misplaced phthalimide intermediates increase waste and toxicity. From experience, automating steps like crystallization and filtration reduces human error, boosting safety and keeping contamination out. Training in personal protective gear and regular environmental monitoring — air quality, surface contamination — matters more for facilities handling kilogram or larger scales. Waste disposal — key for any phthalimide derivative — follows a clear path: categorize as hazardous, avoid simple drainage, and neutralize under supervision. Possible improvements include investment in closed-system transfer for powders, real-time moisture detection, and exploring greener solvents for process steps to curb organic emissions.
Chemists, pharmaceutical manufacturers, and industrial engineers cross paths with 3-(R)-Piperidinyl Phthalimide D-(-)-tartaric acid, not because it’s flashy, but because it solves hard stereochemistry problems and forms a backbone for new drugs in development. Its properties, from density to stability, must be measured, posted, and enforced for every lot. Backed by well-documented structure and consistent physical parameters, this material links advanced synthesis and product safety. That chain of trust stretches from the supplier’s drum to the researcher’s beaker, showing the untold hours of refining, crystallizing, and standardizing that keep labs and production lines moving toward safer, more effective results.